SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending sharply lower after announcing that Marvell canceled all purchase orders inherited from its acquisition of Celestial AI due to an alleged breach of confidentiality. Investors and community members are expressing significant frustration over management's handling of the disclosure, leading to widespread speculation about the company's future contracts and immediate valuation.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing intensified volatility as investors weigh a major workforce efficiency shift alongside broader software sector weakness, with market attention laser-focused on upcoming earnings for signals that AI infrastructure investments are successfully translating into Azure revenue growth.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors react to the topline Phase 3 HAELO clinical trial results for lonvo-z, which met its primary and key secondary endpoints in treating hereditary angioedema. While some in the community celebrate the achievement as a historic milestone for in vivo CRISPR therapy, others are expressing disappointment that the data did not outperform existing treatments as significantly as expected, fueling ongoing volatility and debate over the stock's future valuation.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is attracting intense investor interest as the company prepares for an oral presentation of its pancreatic cancer data at the upcoming Digestive Disease Week conference. The community is buzzing with anticipation over a strong pipeline of clinical catalysts, with many retail traders actively accumulating shares in expectation of a significant breakout.

Greenland Energy Co. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 23, 2024 and is headquartered in New York, NY.

Greenland Energy Co.

Greenland Energy is trending as investors weigh its aggressive 2026 arctic drilling ambitions against the volatility common in low-float energy plays. Community discourse is heavily polarized, with proponents citing the strategic value of oil reserves outside the Strait of Hormuz, while skeptics warn of potential dilution and the long timeline before production.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble Inc. is seeing intense community speculation as investors anticipate a major short squeeze, driven by record high short interest and limited share availability. Enthusiastic supporters are highlighting the potential impact of Rumble's pending acquisition of Northern Data and strategic financial backing from Tether as catalysts that could fundamentally shift the stock's valuation.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending as retail and institutional investors capitalize on its pivot into high-margin custom AI silicon and optical connectivity, with community discourse centered on potential hyperscaler partnerships and structural demand for its networking infrastructure. Traders are closely monitoring the stock's parabolic ascent, fueled by reports of custom chip collaborations and significant options flow, as the community debates whether the momentum represents an infrastructure-led re-rating or a classic overextended squeeze.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as it accelerates its U.S. flight testing schedule, most notably with FAA-authorized demonstrations in New York City, sparking intense community debate over its competitive lead against sector peers. Investors remain focused on the company's progress toward commercial certification and the expansion of its military and urban air mobility partnerships.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

The Direxion Daily Semiconductor Bear 3X Shares (SOXS) is trending as traders grapple with a historic, parabolic rally in the semiconductor sector that has triggered intense debate over whether the market is in a bubble or a sustainable growth cycle. Community sentiment is deeply polarized, with many investors aggressively betting on an imminent mean reversion after eighteen consecutive green days for the underlying chip stocks, while others warn of the inherent risks of holding leveraged inverse instruments against such strong upward momentum.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the Consumer and Business segments. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon is trending as investors rotate into defensive, high-dividend yield stocks amid broader market volatility and uncertainty. The stock is attracting significant attention following recent subscriber growth, a major share buyback announcement, and optimism regarding the company's competitive position in wireless and fiber services.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Jefferies Financial Group Upgrades Black Diamond Therapeutics (NASDAQ:BDTX) to Strong-Buy

Jefferies Financial Group upgraded shares of Black Diamond Therapeutics to a "strong-buy" rating in a report on Thursday...

BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize

Black Diamond Therapeutics bets on brain-penetrant EGFR drug silevertinib, targeting C797S resistance and CNS metastases as key edge in crowded lung cancer market.

BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right

Black Diamond Therapeutics hinges on silevertinib, with 2026 data on progression-free survival and durability set to determine whether its single-asset story can justify upside.

Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and Risks

BDTX rides on silevertinib, with 2026 durability data set to test early NSCLC efficacy and CNS signals, making upcoming readouts a decisive swing factor.

Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?

Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Consensus Rating of "Moderate Buy" from Analysts

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight analysts that are currently covering the firm, MarketBeat reports...

BDTX and Brain Metastases: Why CNS Activity Could Matter in 2026

BDTX spotlights silevertinib's 86% CNS response in NSCLC, with 2026 durability data and a glioblastoma push shaping its brain-metastasis strategy.

Black Diamond Stock: Weighing Catalysts vs. Concentration

BDTX hinges on silevertinib's mutation breadth and CNS activity, with 2026 data, cash runway, and partnership moves set to shape its high-risk, high-reward path.

BDTX: What Silevertinib Data Say About EGFR NSCLC Upside

BDTX bets on silevertinib's broad EGFR mutation reach and CNS activity, but with no approved products, upcoming 2026 data and partnerships are pivotal.

Black Diamond Therapeutics (NASDAQ:BDTX) Stock Price Up 2%  - Should You Buy?

Black Diamond Therapeutics (NASDAQ:BDTX) Trading Up 2% - Should You Buy...

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.19	--	--	N/A
Q4 '25	-$0.18	-$0.27	-50.93%	MISSED
Q3 '25	-$0.23	-$0.15	35.98%	BEAT
Q2 '25	-$0.25	-$0.19	23.23%	BEAT
Q1 '25	$0.02	$0.98	4490.16%	BEAT

BDTX
Black Diamond Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest BDTX News

BDTXBlack Diamond Therapeutics Inc